Bristol-Myers Squibb stock remains a strong buy option

Bristol-Myers Squibb is a major pharmaceutical company. An analyst recently announced a "Buy" rating for its stock. This suggests the stock is expected to perform well in the future. The analyst believes the company has potential for growth, despite currently having a high level of debt. The positive outlook is based on recent developments and market trends. Investors may find opportunities in Bristol-Myers Squibb, especially considering the ongoing demand for its products. The company is involved in important research and development, which could lead to new treatments. The analyst emphasizes their personal investment in the stock. This shows confidence in the company's future direction, although they also note that past performance does not guarantee future results.